AbbVie has finalized its $10.9 billion acquisition of Apogee Therapeutics, enhancing its immunology portfolio with Apogee's late-stage drug candidates targeting inflammatory diseases like atopic dermatitis and asthma. Apogee's lead asset, zumilokibart, showed promising Phase 2 results for skin clearance and itch reduction with convenient dosing schedules. AbbVie expects some short-term earnings dilution but foresees long-term growth and innovation by integrating Apogee's pipeline and expertise. The acquisition supports AbbVie's strategy to expand treatment options for immune-related conditions and maintain leadership in immunology.
AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, enhancing its drug pipeline in immunology, oncology, neuroscience, and aesthetics. The deal causes only modest near-term earnings dilution. AbbVie's Q2 results beat expectations, dr...
AbbVie announced positive Phase 3 results for etentamig, a BCMA x CD3 bispecific T-cell engager, in treating triple-class exposed relapsed/refractory multiple myeloma. The CERVINO study showed etentamig achieved a 74% objective response rate and a 60...
AbbVie announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company's management will engage in a fireside chat at 9:00 a.m. Central time, which will be accessible via a live audio we...
JPMorgan's JEPI ETF offers an 8.33% yield mainly from option premiums and large-cap stocks, but in taxable accounts, most distributions are taxed as ordinary income, not at the lower qualified dividend rate. This results in a significant tax penalty—...
Allergan Aesthetics, part of AbbVie, introduced two new skincare products under the SkinMedica brand: Barrier Calming Cream and HA 5 Hydra Collagen Facial Mist. The Barrier Calming Cream, featuring Calcium Strengthening and Botanical Calming Complexe...
